An ongoing recruiting study at the Comprehensive Cancer Center of the Medical University of Vienna and Vienna General Hospital receives a lot of attention in the current nature. A feature reports on the future of precision therapy for cancer. Under the leadership of hematologist Philipp Staber from the Department of Medicine I, an innovative treatment strategy is being tested that involves testing drugs on the patient's own cancer cells. The study by Staber's group is thus "the first to directly compare functional and genome-guided approaches with treatments based on standard pathology and medical intuition." The nature News feature uses international examples to show the current status and potential opportunities of functional precision medicine in cancer, and Anthony Letai, hematologist at the Dana-Farber Cancer Institute in Boston, Massachusetts, and President of the Society for Functional Precision Medicine, says of the study at the Medical University of Vienna: "This will be a very powerful study that will likely confirm the utility of these functional tests." If you are interested in a collaboration, please contact Philipp Staber directly.
nature: The future of precision cancer therapy might be to try everything
